Sansure Biotech Secures EU IVDR CE Certification for Five Nucleic Acid Diagnostic Kits
Sansure Biotech Inc. (SHA: 688289) announced that five of its nucleic acid diagnostic kits have...
Viral hepatitis
Sino Biopharmaceutical Subsidiary Secures NMPA Approval for IM-101 Therapeutic Vaccine in Chronic Hepatitis B
Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Limited (HKG:...
Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B
Amoytop Biotech (SHA: 688278) announced today that its investigational drug ACT201 has received clinical trial...
Fosun Pharma Invests RMB 220 Million in Hepa Thera, Becomes Second Largest Shareholder in Liver Disease Biotech
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced its participation in a...
Gilead Sciences Secures FDA Accelerated Approval for Hepcludex as First US Treatment for Hepatitis Delta Virus
The U.S. Food and Drug Administration (FDA) granted accelerated approval to Gilead Sciences, Inc. (NASDAQ:...
AbbVie Secures CHMP Positive Opinion for MAVIRET in Acute Hepatitis C Treatment Across All Age Groups
AbbVie Inc. (NYSE: ABBV) announced that the Committee for Medicinal Products for Human Use (CHMP)...
Brii Biosciences Presents Promising HBsAg Rebound Data for Elebsiran-Based Regimens at APASL 2026, Highlighting Potential Functional Cure Profile in Chronic Hepatitis B
Brii Biosciences (HKG: 2137) unveiled a cross-study pooled analysis of hepatitis B surface antigen (HBsAg)...
Amoytop Biotech Inks $445M Deal with Aligos for China Rights to Novel Hepatitis B Capsid Modulator Pevifoscorvir
Amoytop Biotech Co., Ltd. (SHA: 688278), a leading Chinese biopharmaceutical company, has entered into a...
Roche Launches cobas MPX-E Test in CE Markets, Consolidating Four-Virus Detection for Enhanced Blood Safety
Roche AG (SWX: ROG, OTCMKTS: RHHBY) has announced the commercial launch of its cobas MPX-E...
GSK’s Bepirovirsen Receives EMA Review Acceptance for Chronic Hepatitis B, Pioneering Triple-Mechanism ASO Therapy
GlaxoSmithKline plc (GSK, NYSE: GSK) announced that the European Medicines Agency (EMA) has accepted for...
GSK Partners with SPH Keyuan Trade to Relaunch Engerix B – Hepatitis B Vaccine Targets China’s Adult Self-Paid Market
GlaxoSmithKline (GSK; NYSE: GSK) formed a strategic alliance with SPH Keyuan Trade, a China pharmaceutical...
SicaGene’s SG12 ASO Wins NMPA Approval – Antisense Oligonucleotide Targets Hepatitis B Functional Cure
SicaGene (Beijing) Biotechnology Co., LTD announced that SG12 injection, a self-developed antisense oligonucleotide (ASO), has...
GSK Reports 7% Revenue Growth to $44.7 Billion in 2025; Oncology Surges 43%
GlaxoSmithKline plc (GSK, NYSE: GSK) delivered strong 2025 financial results, with total revenues rising 7% in...
Sino Biopharm’s TQA3605 Meets Endpoint in Hepatitis B Phase II Trial
Sino Biopharmaceutical Ltd (HKG: 1177) announced that its Category 1 drug TQA3605 has met the primary...
Huahui Health’s Libevitug Wins NMPA Approval as World’s First HDV Antibody Therapy
Huahui Health announced that China’s National Medical Products Administration (NMPA) has granted conditional approval for...
Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon‑2 After NMPA Feedback
Kawin Technology (SHA: 688687) announced it has voluntarily withdrawn its market filing for peginterferon alfacon‑2...
EPI-003 Wins FDA IND as First LNP Epigenetic Therapy for Hepatitis B
Epigenic Therapeutics (Shanghai) Biotechnology Co., Ltd., a clinical‑stage biotech focused on epigenetic modulation therapies, announced...
RiboLife’s RBD1016 Earns EMA Orphan Designation with RiboGalSTAR Platform
Suzhou Ribo Life Science Co., Ltd. and its subsidiary Ribocure Pharmaceuticals AB announced today that...
Amoytop Biotech Secures NMPA Approval for Pegbinterferon Combination Therapy in Chronic Hepatitis B
Amoytop Biotech Co. Ltd. (SHA: 688278) announced today that the National Medical Products Administration (NMPA)...
Youcare Pharma Secures FDA Approval for YKYY013, a Novel siRNA Therapy for Chronic Hepatitis B
Youcare Pharmaceutical Group (SHA: 688658) announced that the U.S. Food and Drug Administration (FDA) has...